ArticleDiscover oncology2025
Comprehensive multi-omics analysis of histone acetylation modulators identifies ASH1L as a novel aggressive marker for osteosarcoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma, a highly malignant bone tumor prevalent in children and adolescents, continues to have poor long-term survival rates, particularly in metastatic cases. While histone acetylation dysregulation has been implicated in cancer progression, the role of histone acetylation modification-related proteins (HAMRPs) in osteosarcoma immune infiltration and prognosis remains unclear.
methodsThe expression patterns, prognostic implications, and clinical correlations of HAMRPs in osteosarcoma were analyzed using the TARGET, GEO, TISCH, and HPA databases. The effectiveness of HAMRPs in predicting the immune landscape of osteosarcoma was confirmed using CIBERSORT, ssGSEA, and ESTIMATE algorithms. The study employed GSEA analysis, wound healing assay, Transwell, and western blot to explore the role and regulatory mechanism of the key gene ASH1L in osteosarcoma progression.
resultsTwo distinct histone acetylation modification patterns were identified, showing significant differences in survival, clinical features, and immune landscape. Comprehensive clinical correlation analysis and Kaplan-Meier analysis of all HAMRPs used for two subtypes revealed that higher ASH1L expression was found in metastatic osteosarcoma cases and indicated poorer survival outcomes. In vitro experiments confirmed that ASH1L promoted osteosarcoma metastasis and epithelial-mesenchymal transition via the AKT/mTOR pathway. Additionally, an ASH1L-derived risk model was developed to aid personalized clinical decisions.
conclusionsThis study elucidates the prognostic and immunological significance of HAMRPs and highlights ASH1L as a novel aggressive marker in osteosarcoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.